In addition to Stephen Isaacs, 5 other ADRO executives reported Sell trades in the last month.
Currently, Aduro BioTech has an average volume of 257.3K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $17.50, reflecting a 159.3% upside.
The insider sentiment on Aduro BioTech has been negative according to 49 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Stephen Isaacs’ trades have generated a -30.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes.